In Vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in Human Chordoma Xenografts [RNA-seq]
Ontology highlight
ABSTRACT: We evaluated the tumor efficacy of the CDK4/6 inhibitor palbociclib in two chordoma Patient’s Derived Xenograft (PDX) models to validate and identify novel therapeutic approaches.
ORGANISM(S): Homo sapiens
PROVIDER: GSE216418 | GEO | 2022/10/29
REPOSITORIES: GEO
ACCESS DATA